All News

Article

Difficult-to-treat RA: are we any closer to predicting who is at risk?

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA Jun 16, 2024

It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.

Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. https://t.co/Q7CZoHpDmc https://t.co/cvIRhBJt9Z

Pain in RA: Different Drugs for Different Mechanisms | RheumNow

Matters of the heart: cardiovascular disease and mortality in RA Patients with RA have up to 2x higher risk of coronary artery disease, plus increased atrial fibrillation and stroke risk. https://t.co/wFs7ds3tF2 https://t.co/GWyXJbeyIn

Matters of the heart: cardiovascular disease and mortality in RA | RheumNow

Mechanistic Promise in RA Doesn’t Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria. https://t.co/PcKtezJLCH https://t.co/N9tdgFN7Xq

https://buff.ly/4ciOhFX

Dual seropositivity and shared epitopes in RA: friends or foes? Dual seropositivity, RF and/or anti-citrullinated protein antibodies (ACPA) as well as shared epitope (SE) are known to be associated with poor prognosis and structural damage in RA. https://t.co/QcTHpgPV2Q https://t.co/TzueMr8M5T

Dual seropositivity and shared epitopes in RA: friends or foes? | RheumNow

EULAR 2024: New drugs for RA? Abiprubart is an Abatacept distant relative, targeting T cell activation through a different target/molecular interaction (CD40/CD154). https://t.co/3wAGjfCdcN https://t.co/2YK2OeIVZK

EULAR 2024: New drugs for RA? | RheumNow

How many #autoantibodies Does one need in #rheumatoid #arthritis Need 4 citrullinated peptides Covers off 97% of IgG CVP2 ACPAs #EULAR2024 @RheumNow @eular_org https://t.co/LNFGuFXGrC

https://twitter.com/aurelierheumo/status/1801923768530465116

#EULAR2024 POS0467 - Periodontal disease related tot he development of #RA ACPA positive and negative pts. Tooth extraction in CCP positive pts was associated. Need tooth history in RA. @RheumNow https://t.co/b9Nb3cd0kd

Could dogs smell RA? lol...! Exhaled breath experimental study to diagnose RA? Volatile organic compounds can detect RA? #EULAR2024 @RheumNow https://t.co/FiHsZ522In

Deep B cell depletion strategies for Drug resistant RA @RheumNow #EULAR2024 for those which dont want to use CAR-T cells / other options. Maybe used in other diseases. https://t.co/joRhfWaiDs

EULAR OP0041 (2024) COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

EULAR Abstract Archive

EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

EULAR Abstract Archive

#EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signalling pathways assoc with pathotype & response to RTX & TOC Study highlights active signalling pathways assoc with pathotype & drug response OP0218 @RheumNow https://t.co/RZMSgj9T6k

https://twitter.com/DrMiniDey/status/1801949440451723370/photo/1

Spatial transcriptomics work highlighted at #EULAR2024 @RheumNow https://t.co/5NvX1PW2tA

Basic Science highlights at #EULAR2024 @RheumNow https://t.co/gr3Mysp3f4

https://twitter.com/bella_mehta/status/1801947647625846910/photo/1

Photos of hands/finger folds for RA disease activity - nice idea, challenges++, but with poor photo quality you’re always struggling. Telehealth has taught us: - ideal settings can work, but - suboptimal inputs inevitably lead to suboptimal results #EULAR2024 POS0451 @RheumNow https://t.co/fyCQzSl6tB

https://twitter.com/drdavidliew/status/1801946507798818922/photo/1

Have RA and want to get pregnant? What can you do? The answer is simple: disease control. Implementing T2T in RA led to much better fertility. RA therapy is your friend! #EULAR2024 POS0436 Rotterdam @RheumNow https://t.co/aoxNakMix1

OP0007 (2024) S/C ABA VS ADA H2H COMPARISON ADULTS EARLY, DUAL SEROPOSITIVE RA, +ive FOR SHARED EPITOPE HLA CLASS II RISK ALLELES, & INADEQUATE RESPONSE TO MTX: RESULTS FROM PH3 AMPLIFIED TRIAL shame seropositivity did not translate to an advantage for AbA @RheumNow #EULAR2024

Another proof (if needed) that controlling DA in RA is a very important preventive measure in RA! 179 pts ILD newly developed 9.5% progressed 12.3% no change 74.9% improved 4.5% 5.7% in the LDA group 28.0% non-LDA group (p=0.006) @RheumNow #EULAR2024 POS0408 https://t.co/7DyXr5zdCM

https://twitter.com/AurelieRheumo/status/1801941874539683876/photo/1

POS0061 (2024) INTERCEPTION OF THE DEVELOPMENT OF RA BY 1-YEAR MTX IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RA: 4 YEAR RESULTS OF THE TREAT EARLIER TRIAL MTX reduced development of RA in high risk acpa neg pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

EULAR Abstract Archive

Topics

All News

Difficult-to-treat RA: are we any closer to predicting who is at risk?

Do you get our email newsletter?